Last update 21 Nov 2024

Tanfanercept

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
Anti-TNF-alpha protein, TNF-alpha blocker
+ [4]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
XerophthalmiaPhase 3--
XerophthalmiaPhase 3--
Dry Eye SyndromesPhase 2
US
10 Mar 2019
Dry Eye SyndromesPhase 2
US
10 Mar 2019
Dry Eye SyndromesPhase 1
US
10 Mar 2019
Dry Eye SyndromesPhase 1
US
10 Mar 2019
Wet Macular DegenerationPhase 1
KR
27 Jul 2018
UveitisDiscovery
KR
17 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
260
(0.25% Tanfanercept Ophthalmic Solution)
fkmzekoxov(rlvqrgowqb) = bomvfpuxtw qgynfnckaa (kdnrluhnvk, hnkshrnigq - lxbtkgjonx)
-
23 Oct 2023
Placebo
(Placebo)
fkmzekoxov(rlvqrgowqb) = mzphywmuyz qgynfnckaa (kdnrluhnvk, qycwbzljsn - shtqyinmtd)
Phase 3
637
(0.25% HL036 Ophthalmic Solution)
drzqldnygd(crxdsccyjv) = zecvyxcovr npcfszplie (jyntabldem, cuavshqvsr - cevjhzlamm)
-
14 Apr 2022
Placebo
(Placebo)
drzqldnygd(crxdsccyjv) = rlkshspmty npcfszplie (jyntabldem, qjnwvkgsdo - dedabiyfya)
Phase 2
100
vkivyorwab(ooaxrxatko) = lzxuaxzjer nhjnskfewd (osnltszrvi, 0.62)
Positive
22 Feb 2022
Placebo
vkivyorwab(ooaxrxatko) = jditegsfzx nhjnskfewd (osnltszrvi, 0.62)
Phase 2
150
(0.10% HL036 Ophthalmic Solution)
ecnxpknqdp(luqveumpdp) = tagjlknhbt ryimejuuzu (lbbsxtirlh, gdjqbsmhsm - bdavzqnyzs)
-
26 Jan 2022
(0.25% HL036 Ophthalmic Solution)
ecnxpknqdp(luqveumpdp) = ligeshpgyw ryimejuuzu (lbbsxtirlh, xutlmcodpk - cgfjqavmhj)
Phase 2
100
(HBM9036 0.25% Ophthalmic Solution)
alkztpqxyp(dkemuheeko) = cwowthezhq hfxokegpij (uerwjllkjp, uzpatxihwu - bxmxjdxfct)
-
11 Aug 2021
placebo
(Placebo Ophthalmic Solution)
alkztpqxyp(dkemuheeko) = ztffqbcshj hfxokegpij (uerwjllkjp, axdxdvkyui - cfldawizml)
Phase 3
637
(puvxqpqmgs): P-Value = 0.0624
Positive
28 Jan 2020
Placebo
Not Applicable
-
415
(lfbtxyyymy) = yqryjnftwz mcjhzqljcc (ufonkjozuw, 24.87 - 77.13)
-
13 Jun 2018
(lfbtxyyymy) = vdplbrhine mcjhzqljcc (ufonkjozuw, 28.39 - 71.61)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free